Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial

American Heart Journal

Volumn 178, Issue , 2016, Pages 74-84

  Vemulapalli, Sreekanth ^a   Hellkamp, Anne S ^a   Jones, W Schuyler ^a   Piccini, Jonathan P ^a   Mahaffey, Kenneth W ^b   Becker, Richard C ^c   Hankey, Graeme J ^d   Berkowitz, Scott D ^e   Nessel, Christopher C ^f   Breithardt, Günter ^g   Singer, Daniel E ^h   Fox, Keith A A ⁱ   Patel, Manesh R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e BAYER CORPORATION   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ADVERSE OUTCOME; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHAD; COMPARATIVE STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; BLOOD PRESSURE; CHEMICALLY INDUCED; COMPLICATION; DIET THERAPY; HEMORRHAGE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; EMBOLISM; FEMALE; HEMORRHAGE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK; RIVAROXABAN; STROKE; WARFARIN;

EID: 84973315135     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.05.001     Document Type: Article

References (25)

1. W.A. Wattigney, G.A. Mensah, and J.B. Croft Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention Circulation 108 2003 711 716
2. T.J. Wang, J.M. Massaro, D. Levy, and et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study JAMA 290 2003 1049 1056
3. E. Rapsomaniki, A. Timmis, J. George, and et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people Lancet 383 2014 1899 1911
4. CDC Vital signs: prevalence, treatment, and control of hypertension - United States, 1999-2002 and 2005-2008 MMWR 60 2011 103 108
5. A.V. Chobanian, G.L. Bakris, H.R. Black, and et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
6. G. Mancia, R. Fagard, K. Narkiewicz, and et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 34 2013 2159 2219
7. R.G. Hart, L.A. Pearce, R. McBride, and et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators Stroke 30 1999 1223 1229
8. R.G. Hart, L.A. Pearce, R.M. Rothbart, and et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators J Am Coll Cardiol 35 2000 183 187
9. Study TSPiAF Risk Factors for thromboembolism during aspirin therapy in patients with atrial fibrillation J Stroke Cerebrovasc Dis 5 1995 147 157
10. J.C. van Latum, P.J. Koudstaal, G.S. Venables, and et al. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group Stroke 26 1995 801 806
11. T.P. Van Staa, E. Setakis, G.L. Di Tanna, and et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice J Thromb Haemost 9 2011 39 48
12. G.Y. Lip, L. Frison, M. Grind, and et al. Effect of hypertension on anticoagulated patients with atrial fibrillation Eur Heart J 28 2007 752 759
13. M.P. Rao, S. Halvorsen, D. Wojdyla, and et al. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial J Am Heart Assoc 4 2015 [pii: e002015]
14. R. Nagarakanti, L. Wallentin, H. Noack, and et al. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial) Am J Cardiol 116 2015 1204 1209
15. C.T. January, L.S. Wann, J.S. Alpert, and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 64 2014 e1 e76
16. A.J. Camm, G.Y. Lip, R. De Caterina, and et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
17. A.J. Camm, P. Kirchhof, G.Y. Lip, and et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
18. M.R. Patel, K.W. Mahaffey, J. Garg, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
19. S. Schulman, C. Kearon, and et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
20. S. MacMahon, R. Peto, J. Cutler, and et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias Lancet 335 1990 765 774
21. D.M. Lloyd-Jones, E.P. Leip, M.G. Larson, and et al. Novel approach to examining first cardiovascular events after hypertension onset Hypertension 45 2005 39 45
22. J. Berwaerts, and J. Webster Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages QJM 93 2000 513 521
23. G.J. Hankey, S.R. Stevens, J.P. Piccini, and et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation Stroke 45 2014 1304 1312
24. M. Banach, and W.S. Aronow Blood pressure j-curve: current concepts Curr Hypertens Rep 14 2012 556 566
25. T.G. Pickering, J.E. Hall, L.J. Appel, and et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research Circulation 111 2005 697 716